መነሻ › ከብላስት ብዛት ጋር ያለ ተቃዋሚ አኒሚያ › Washington
በWashington ለከብላስት ብዛት ጋር ያለ ተቃዋሚ አኒሚያ የሚደረጉ ክሊኒካዊ ጥናቶች
ለከብላስት ብዛት ጋር ያለ ተቃዋሚ አኒሚያ የሚደረጉ 5 ጥናቶች በWashington ባሉ ቦታዎች ተሳታፊዎችን እየፈለጉ ነው።
በWashington ውስጥ ያሉ ከተሞች
Official study text (English)
211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia
- Fred Hutch/University of Washington Cancer Consortium, Seattle
ተሳታዮችን በመፈለግ ላይደረጃ 1/2
እድሜ ከ18 እስከ 75 · ሁሉም ጾታዎች · የተሻሻለው በ22 ጁን 2026 · NCT03128034211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome
- Fred Hutch/University of Washington Cancer Consortium, Seattle
ተሳታዮችን በመፈለግ ላይደረጃ 1/2
እድሜ ከ18 እስከ 75 · ሁሉም ጾታዎች · የተሻሻለው በ22 ጁን 2026 · NCT03670966A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
- Seattle Cancer Care Alliance, Seattle
ተሳታዮችን በመፈለግ ላይደረጃ 2/3
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ30 ኤፕሪ 2026 · NCT04256317A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
- Fred Hutchinson Cancer Center, Seattle
ተሳታዮችን በመፈለግ ላይደረጃ 2
እድሜ ከ18 እስከ 66 · ሁሉም ጾታዎች · የተሻሻለው በ17 ማርች 2026 · NCT06859424HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy
- Fred Hutchinson Cancer Research Center, Seattle
ተሳታዮችን በመፈለግ ላይደረጃ 2
3 Months · ሁሉም ጾታዎች · የተሻሻለው በ12 ኖቬም 2025 · NCT02143830ከ ClinicalTrials.gov የተገኘ መረጃ፣ በ5 ኦክቶ 2026 የተሰብሰቡ። እያንዳንዱ ጥናት የራሱን ቅድመ ሁኔታ ይወስናል፤ የጥናት ቡድኑ ማን መሳተፍ እንደሚችል ይወስናል።